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We report here the anesthetic management of a patient with schizophrenia and pseudocholinesterase deficiency.
Electroconvulsive therapy was performed using succinylcholine and rocuronium as the neuromuscular blocking
agents in the first seven and latter six treatments, respectively. The recovery time from muscle relaxation after
succinylcholine administration was remarkably longer than that after rocuronium-sugammadex administration.
Rocuronium and sugammadex appear to be useful in situations in which succinylcholine is contraindicated.
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Neuromuscular blocking agents (NMBA) and intraven-
ous anesthetics are used during modified electroconvul-
sive therapy (m-ECT). Indeed, bone fractures and
dislocation have been reported when ECT is performed
without appropriate muscle paralysis [1, 2]. The NMBA
used for ECT should have a rapid onset and short dur-
ation of muscle relaxation. Therefore, previously, the
choice of relaxant was limited to succinylcholine (SCC).
However, succinylcholine is not always ideal, as it has
some undesirable side effects, such as the risk of ana-
phylaxis, increasing serum potassium levels, and other
cardiovascular properties [3, 4]. Since, in high doses,
rocuronium (ROC) has a reasonably rapid onset and
can be reversed with sugammadex, it has the potential
to be used in place of succinylcholine [5–8]. We
present here a patient with pseudocholinesterase defi-
ciency in whom a series of m-ECTs was performed with
either SCC or ROC.* Correspondence: takazawt@gunma-u.ac.jp
1Department of Anesthesiology, Gunma University Graduate School of
Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Japan
Full list of author information is available at the end of the article
© 2015 Takazawa et al. Open Access This arti
International License (http://creativecommons.o
reproduction in any medium, provided you giv
the Creative Commons license, and indicate ifCase presentation
A 50-year old man (56.3 kg, 171 cm) with schizophrenia
was scheduled for m-ECT. He had previously undergone
ECT without anesthesia (i.e., unmodified ECT) for about
20 years, which was replaced with m-ECT because he
developed a calcaneal fracture. Although preoperative
blood tests indicated hypoproteinemia (total protein
6.2 g/dl, albumin 2.9 g/dl), his liver and renal functions
appeared to be normal. His current medication included
oral paliperidone (6 mg), aripiprazole (6 mg), chlorpro-
mazine (100 mg, two times per day), and intramuscular
injection of 50 mg risperidone.
After obtaining written informed consent, a series of
m-ECTs was performed. Blood pressure, heart rate,
oxygen saturation, partial pressure of carbon dioxide,
and electrocardiogram were monitored during the pro-
cedure. Ventilation was assisted with a face mask using
100 % oxygen. The electrical stimulus was delivered via
bifronto-temporal electrodes. The dose of propofol and
NMBAs used in each treatment is shown in Table 1.
Pirenzepine (10 mg) was injected to reduce oral dis-
charge and inhibits gastric acid secretion in most cases.
In the first treatment, his spontaneous breathing was not
fully restored even 20 min after the stimulus. Hence, the
anesthesiologist inserted a laryngeal mask just beforecle is distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Table 1 Dose of propofol and neuromuscular blocking agents, seizure duration, and duration for which the patient stayed in the
operation room after the electrical stimulus
Treatment no. Propofol (mg) NMBA (mg) Clinical seizure duration (s) EEG seizure duration (s) Time to shifting from OR (min)
1 50 SCC (40) 21 28 25
2 40 SCC (20) 24 27 22.5
3 40 SCC (10) 45 45 15
4 40 SCC (10) 25 42 15
5 40 SCC (5) 21 22 7.5
6 40 SCC (5) 28 37 7.5
7 40 SCC (6) 43 43 17
8 40 ROC (27) + SUG (250) 18 25 6.5
9 40 ROC (30) + SUG (400) 25 39 7.5
10 40 ROC (30) + SUG (400) 23 37 5.8
11 40 ROC (30) + SUG (200) 31 31 5
12 40 ROC (30) + SUG (200) 31 31 10
13 40 ROC (30) + SUG (400) 34 34 7.5
NMBA neuromuscular blocking agent, SCC succinylcholine, ROC rocuronium, SUG sugammadex
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with a flow inflating bag for 15 min. He remained in the
recovery room for about 50 min and was moved to the
ward after confirming consciousness and stable respir-
ation. In the second treatment, the first spontaneous
breath appeared more than 15 min after the stimulus
despite reducing the SCC dose to 20 mg. SCC was fur-
ther reduced to 10 mg in the third and fourth treatment
sessions; in both cases, the first spontaneous breath ap-
peared 15 min after the stimulus. Finally, the SCC dose
was reduced to 5 mg (0.09 mg/kg) in the fifth treatment
session, with which the time to first spontaneous breath
was shortened to 5 min.
After the first series of m-ECTs, we obtained a sample
of the patient’s blood to uncover the cause of the unex-
pected delayed recovery from muscle relaxation follow-
ing administration of SCC. We also attempted to test
the dose-response to SCC under neuromuscular moni-
toring using a train-of-four (TOF)-Watch SX (Organon,
Roseland, NJ, USA) in the seventh treatment. The data
acquired from the TOF-Watch was stored in a personal
computer via a fiber-optic cable. The ulnar nerve was
supramaximally stimulated with a square pulse of 0.2-ms
duration, delivered as train-of-four (TOF) pulses at
intervals of 15 s. The resulting contractions of the ad-
ductor pollicis muscles were quantified by an accelero-
myographic monitor. Calibration was performed, and
baseline responses were recorded after propofol admin-
istration and before muscle relaxant administration, with
the neuromuscular monitoring continued until he was
moved to the recovery room. For anesthesia induction,
propofol followed by 2 mg SCC was administered in a ti-
trated dose. An additional 2 mg of SCC was adminis-
tered 1 min after the first administration, because thenumber of twitches observed (TOF count) was still four.
At the same time, fasciculation of all the muscles was
observed. Finally, an additional 2 mg (6 mg in total) of
SCC was required 1 min after the second administration
of SCC, because the TOF count was still four. T1 was
assessed as being zero, 75 s after the third administra-
tion. Thereafter, the psychiatrist performed ECT. With
this protocol, the first spontaneous breath was observed
at 11.5 min after the ECT stimulus, and he was moved
to the recovery room at 17.3 min after the stimulus. It
took 19.5 min to recover to a TOF count of four. We ob-
tained the results of the blood tests in the interval be-
tween the seventh and eighth treatments. Again, the
tests indicated normal liver and renal function. However,
his pseudocholinesterase level was extremely low (27 U/
L, normal range 213-501 U/L), suggesting that delayed
recovery from muscle relaxation following the adminis-
tration of SCC was due to pseudocholinesterase defi-
ciency. Hence, we decided to use rocuronium instead of
SCC for future ECTs.
In the eighth treatment session, anesthesia was in-
duced with propofol followed by 17 mg (0.3 mg/kg)
ROC under neuromuscular monitoring. An additional
10 mg of ROC (27 mg in total) was administered
2.5 min after the first administration because the TOF
ratio was 0.33. ECT was performed 1.5 min after the
second administration of ROC. We administered
200 mg sugammadex 1.8 min after the stimulus, result-
ing in appearance of the first spontaneous breath
2.3 min after the electrical stimulus. An additional dose
of 50 mg of sugammadex was administered 4.8 min after
the stimulus because the TOF ratio was still 0.79. He
was moved to the recovery room 6.8 min after the
stimulus, after confirming that the TOF ratio was 0.96.
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the eighth treatment to explore the cause of pseudo-
cholinesterase deficiency, no abnormalities, such as liver
cirrhosis or cancer, were detected. The gastroenterolo-
gist whom we consulted did not find a definitive cause
of the pseudocholinesterase deficiency, although he
pointed out poor nutrition as a candidate etiology. In
the ninth treatment, ECT was performed when T1 was
assessed as being zero, 4 min after ROC administration.
Sugammadex (400 mg) was administered 1 min after the
ECT stimulus. Spontaneous respiration resumed 1 min
after sugammadex administration, and bag mask ventila-
tion was not required 0.5 min thereafter, due to the
adequacy of spontaneous breathing. The TOF ratio re-
covered to ≥0.9, 4.5 min after the ECT stimulus. He was
moved to the recovery room 1.3 min thereafter. Almost
the same anesthesia protocol was followed for the tenth
to thirteenth ECT sessions, although neuromuscular
monitoring was not performed. In our patient, SCC was
used from the first to seventh treatment, while ROC-
sugammadex was used from the eighth to thirteenth ses-
sions (Table 1). Blood tests performed after the last
treatment still demonstrated low values (28 U/L) of
pseudocholinesterase. We then compared the duration
of electroencephalogram (EEG) seizures with SCC vs.
ROC-sugammadex by Mann-Whitney Rank Sum Test
(Fig. 1a) and found no statistically significant difference
between them. The actual duration of seizures measured
by the attending psychiatrist was also not different be-
tween the two NMBAs (data not shown). However, the
duration for which the patient stayed in the operation
room after the stimulus was much longer following ECT
sessions with SCC as compared to those with ROC-
sugammadex (Fig. 1b, P < 0.05, Mann-Whitney Rank
Sum Test).Fig. 1 The comparison of EEG seizure duration (a) and time to
shifting from operation room (b) between treatment with SCC and
ROC-sugammadex. Data are mean ± SD. *P < 0.05, Mann-Whitney
Rank Sum TestDiscussion
We used either SCC or ROC as the NMBA for sequen-
tial m-ECTs in a schizophrenic patient with pseudo-
cholinesterase deficiency that was diagnosed during the
course of ECTs. Although the duration of seizures was
not affected by the choice of NMBA, the combination of
ROC and sugammadex shortened the time to return of
spontaneous respiration, and hence, the time for which
the patient stayed in the operation room after the ECT.
To our knowledge, this is the first report comparing the
effect of SCC and ROC during m-ECT in a single pa-
tient with pseudocholinesterase deficiency.
We previously reported the potential benefit of a com-
bination of ROC-sugammadex as an alternative to SCC
for muscle relaxation during ECT [5, 6, 9]. In patients
without pseudocholinesterase deficiency, 8 mg/kg sugam-
madex produced equally rapid recovery from ROC-induced
(0.6 mg/kg) muscle relaxation compared with spontaneous
recovery from 1 mg/kg SCC during ECT [6]. In the
present patient, we used 200–400 mg sugammadex
(5.5 ± 1.8 mg/kg) for reversal of ROC (0.52 ± 0.02 mg/
kg), while the dose of SCC used was 5–40 mg (0.24 ±
0.23 mg/kg), which is much smaller than the usual dose
(i.e., 1 mg/kg).
Although monitoring the TOF ratio seems to be a
good method for assessing NMBA effect during ECT
with non-depolarizing NMBAs, the TOF ratio has uncer-
tain significance following administration of a single
dose of SCC [10]. To overcome this problem, TOF count
was used instead of TOF ratio to estimate the effect of
SCC in the seventh treatment. We did not compare the
time to recovery from muscle relaxation between SCC
and ROC-sugammadex, because neuromuscular moni-
toring was only performed during some of the treat-
ments. A definitive comparison of the NMBAs would
require stringent documentation of the time to recovery
of T1 to 10 and 90 % [5–7].
In this patient, the time to the first spontaneous breath
after electrical stimulation in the seventh treatment was
11.5 min, while it was 2.3 and 2 min in the eighth and
tenth treatments, respectively. The anesthesiologist per-
mitted the patient to be shifted from the operation room
to the recovery room once his spontaneous breathing
was deemed stable enough. The duration that the patient
remained in the operation room after electrical stimula-
tion was much shorter when a combination of ROC-
sugammadex was used, as shown in Fig. 1b, suggesting
faster recovery from muscle relaxation with ROC-
sugammadex.
Seizure duration was comparable between treatment
with SCC and ROC-sugammadex, as shown in Fig. 1a.
This was inconsistent with our previous report which
showed longer seizure duration with ECT following
ROC administration than that with SCC administration
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which NMBAs were used in this ECT series. Indeed, the
number of sessions of ECT seems to affect seizure dur-
ation, because of improvement in the depressive condi-
tion with ECT. Hence, the use of ROC following that of
SCC may mask the longer ECT seizure duration with
ROC administration.
The relatively high cost of ROC-sugammadex reduces its
advantages during ECT [11]. Indeed, in the UK, use of
ROC-sugammadex (4 mg/kg) for ECT reportedly increases
the cost of the drugs used during ECT by 170 times as
compared to SCC administration (£125.29 vs. £0.71) [11].
In our ECT series, the average drug cost, including
anesthetic and vasoactive agents for ECT, calculated from
the database of the Japan Ministry of Health, Labor, and
Welfare, was six times higher for treatment with ROC-
sugammadex than with SCC (¥17,328 vs. ¥2,885).
Recent evidence demonstrated a risk of anaphylaxis
following administration of sugammadex [12, 13], al-
though anaphylaxis induced by muscle relaxants, includ-
ing SCC and ROC, is not rare. A recent report from
France demonstrated that NMBAs were the cause of
perioperative anaphylaxis in more than half the cases
and that SCC was the causative NMBA in more than
60 % of such cases [14]. However, it is difficult to deter-
mine which NMBA is more likely to induce anaphylaxis.
This is because the frequency of use of NMBAs is
unknown. Besides anaphylaxis, SCC has a range of side
effects, as mentioned before. Given the varied contrain-
dications to the use of SCC, ROC may be a safer NMBA
for ECT, particularly when it is used with sugammadex.
The advantages of use of ROC-sugammadex for ECT, in-
cluding fast recovery from muscle relaxation and fewer side
effects, may outweigh the high cost of its usage. The super-
iority of ROC-sugammadex for ECT is even more obvious
in subjects with pseudocholinesterase deficiency, since
spontaneous recovery from muscle relaxant effects after
SCC is expected to be markedly prolonged in such cases.
Conclusions
ROC administration followed by sugammadex reversal
of neuromuscular blockade seems to be better than suc-
cinylcholine for ECT, particularly in patients with
pseudocholinesterase deficiency. Moreover, the useful-
ness of ROC and sugammadex for ECT may be extended
to patients in whom the use of SCC is contraindicated,
such as those with severe osteoporosis, amyotrophic lat-
eral sclerosis, and a history of neuroleptic syndrome.
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